Browse
Submit Data
Databases
API
Help

Dataset Information

0 Views

0 Connections

0 Citations

0 Reanalyses

0 Downloads

Omics score: 0

RNA-seq in liver cancer cell and cinobufagin treatment cells

ABSTRACT: RNA-seq in liver cancer cell and cinobufagin treatment cells

PROVIDER: PRJNA597601 | ENA |

REPOSITORIES: ENA

ACCESS DATA

Json Xml

Similar Datasets

RNA-seq in liver cancer cell and cinobufagin treatment cells

Project description:Cinobufagin, belonged to a kind of cardiotonic steroids (CSs), derived from the extracts of toad venom, which presented the significant anticancer properties as inhibitors of Na+/K+-ATPase (NKA) in many cancer cells. Nowadays, cinobufagin was usually used to apply for clinical treatments of patients in advanced stage of cancer, and improved their quality of life and prolonged their survival period. Unfortunately, long-term drug treatment had also led to multi-drug-resistance (MDR) likely other chemotherapy drugs. However, this detailed mechanism was not still clear. In the present study, we noticed that cinobufagin could trigger the protective autophagy to suppress cells apoptosis in liver cancer HepG2 and Huh-7 cells by inhibition of PI3K-AKT-mTOR pathway using RNA-seq method. We also confirmed that cinobufagin could inhibit cells proliferation and induce cells apoptosis, and generated cells autophagy by up-regulation expression of LC3B-II, Beclin 1 and Atg12-atg5. More importantly, autophagy inhibitor (MRT68921) enhances the anti-proliferation and pro-apoptosis effects of cinobufagin in HCC cells. Therefore, we thought that a combination of cinobufagin and autophagy inhibitors may be a potential effective strategy in treatment of HCC.

2019-12-26 | GSE142588 | GEO

Kinetics after JQ1 treatment in liver cancer cell

Project description:Analysis of global gene expression after BRD4 inhibition by JQ1 in liver cancer cell lines SK-Hep1 Total RNA obtained from human liver cancer cell line SK-Hep1 cells after treatment of JQ1

2016-07-20 | E-GEOD-75908 | biostudies-arrayexpress

RNA-seq of liver tissue and liver cancer cell lines

Project description:RNA-seq of liver tissue and liver cancer cell lines

| PRJEB11781 | ENA

RNA-seq of Liver Cancer

Project description:The French ICGC project on liver tumors is coordinated by Pr Jessica Zucman-Rossi and funded by Inca (French Institute for Cancer). The aim of the present project is to identify the catalog of somatic and germline mutations in liver tumors using whole genome (WGS) and whole exome sequencing (WGS), integrated with DNA methylation and RNA sequencing (RNA-seq) data. The present series corresponds to 161 RNA-seq samples from tumors with matched WES or WGS. Hepatocellular carcinoma (HCC) accounts for more than 90% of liver cancers, and is a major health problem. It is the 3rd cause of cancer-related mortality. Advances in genomic analyses have formed a comprehensive understanding of different underlying pathobiological layers resulting in hepatocarcinogenesis. Thus, the development of next-generation sequencing technologies has made it possible to generate more comprehensive catalogues of somatic alteration events (single nucleotide substitutions, structural variations, and epigenetic changes) in liver cancer genome than ever before.

| EGAS00001002879 | EGA

Sequencing of liver cancer cell lines

Project description:Liver cancer is a dreadful disease with limited therapeutic options. How to translate genomic findings into biomarkers and precision treatment is challenging. A large cell line-based platform was established, termed as Liver Cancer Model Repository. Heterogeneities in patients were faithfully recapitulated by 81 liver cancer cell lines at genomic and transcriptomic levels. This platform provides a rich resource and models to study cancer drivers and drug responses in liver cancer.

| EGAS00001002237 | EGA

ChIP-seq in liver cancer HepG2 cells

Project description:ChIP-seq in liver cancer HepG2 cells

| PRJNA542691 | ENA